Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) …
JR Nebeker, R Virmani, CL Bennett, JM Hoffman… - Journal of the American …, 2006 - jacc.org
Objectives: We undertook the review of all available cases of hypersensitivity reactions after
placement of a drug-eluting stent (DES) and classified potential causes. Background: Six …
placement of a drug-eluting stent (DES) and classified potential causes. Background: Six …
Off‐label drug use in oncology: a systematic review of literature
What is known and objective The off‐label use of medicines is widespread in several
diseases. This type of prescribing practice is particularly more acute in oncology. However …
diseases. This type of prescribing practice is particularly more acute in oncology. However …
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and …
KR Carson, AM Evens, EA Richey… - Blood, The Journal …, 2009 - ashpublications.org
Rituximab improves outcomes for persons with lymphoproliferative disorders and is
increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients …
increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients …
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
D Hershman, AI Neugut, JS Jacobson… - Journal of the …, 2007 - academic.oup.com
Background Recently, increasing numbers of women receiving adjuvant chemotherapy for
breast cancer have also received granulocyte colony-stimulating factors (G-CSFs) or …
breast cancer have also received granulocyte colony-stimulating factors (G-CSFs) or …
Cyclooxygenase inhibition and cardiovascular risk
EM Antman, D DeMets, J Loscalzo - Circulation, 2005 - Am Heart Assoc
Over the past several months clinicians have been con-fronted at an escalating rate with
reports describing the risks of COX-2 inhibitors (coxibs). Information on this class of drugs …
reports describing the risks of COX-2 inhibitors (coxibs). Information on this class of drugs …
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or …
SM Trifilio, CL Bennett, PR Yarnold… - Bone marrow …, 2007 - nature.com
Zygomycosis is increasingly reported as a cause of life-threatening fungal infections. A
higher proportion of cases reported over the last decades have been in cancer patients, with …
higher proportion of cases reported over the last decades have been in cancer patients, with …
AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program
R Chou, N Aronson, D Atkins, AS Ismaila… - Journal of clinical …, 2010 - Elsevier
Comparative effectiveness reviews (CERs) are systematic reviews that evaluate evidence
on alternative interventions to help clinicians, policy makers, and patients make informed …
on alternative interventions to help clinicians, policy makers, and patients make informed …
User involvement in healthcare technology development and assessment: structured literature review
S Ghulam Sarwar Shah, I Robinson - International Journal of Health …, 2006 - emerald.com
Purpose–Medical device users are one of the principal medical device technology
stakeholders. The involvement of users in medical device technology development and …
stakeholders. The involvement of users in medical device technology development and …
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review …
BJ Edwards, AD Bunta, J Lane, C Odvina, DS Rao… - JBJS, 2013 - journals.lww.com
Background: In the United States, hip fracture rates have declined by 30% coincident with
bisphosphonate use. However, bisphosphonates are associated with sporadic cases of …
bisphosphonate use. However, bisphosphonates are associated with sporadic cases of …
Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study
KR Page, F Sifakis, RM De Oca… - Archives of Internal …, 2006 - jamanetwork.com
Background Treatment of latent tuberculosis infection (LTBI) is an important aspect of
tuberculosis control in the United States, but the effectiveness of this strategy is …
tuberculosis control in the United States, but the effectiveness of this strategy is …